Melatonin in patients with cancer receiving chemotherapy: A randomized, double-blind, placebo-controlled trial

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 7327-7337

  Sookprasert, Aumkhae ^a   Johns, Nutjaree Pratheepawanit ^b,c   Pnunmanee, Anakapong ^a   Pongthai, Parichart ^d   Cheawchanwattana, Areewan ^a   Johns, Jeff ^c   Konsil, Julraht ^c   Plaimee, Preeyaporn ^c   Porasuphatana, Supatra ^a   Jitpimolmard, Suthiphan ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b Faculty of Pharmaceutical Sciences   (Thailand)

^c KHON KAEN HOSPITAL   (Thailand)

^d Faculty of Pharmaceutical Sciences   (Thailand)

Author keywords

8 dihydro 2' deoxyguanosine; 8 oxo 7; 8 oxodG; Cancer; Chemotherapy; Clinical trial; Melatonin; Quality of life

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELATONIN; PACLITAXEL; 8-OXO-7-HYDRODEOXYGUANOSINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; DEOXYGUANOSINE; PLACEBO;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROPATHY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DNA DAMAGE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYGUANOSINE; DISEASE-FREE SURVIVAL; DNA DAMAGE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MELATONIN; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84918577911     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. D'Addario G, Felip E and Group ObotEGW: Non-small cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: 68-70, 2009
2. Navada S, Lai P, Schwartz A and Kalemkerian G: Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J Clin Oncol 24: 7082, 2006
3. Guibert N, Mazieres J, Lepage B, Plat G, Didier A and Hermant C: Prognostic factors associated with interventional bronchoscopy in lung cancer. Ann Thorac Surg 97: 253-259, 2014
4. Soo RA, Loh M, Mok TS, Ou SH, Cho BC, Yeo WL, Tenen DG and Soong R: Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-Analysis of randomized controlled trials. J Thorac Oncol 6: 1030-1038, 2011
5. Iyer S, Roughley A, Rider A and Taylor-Stokes G: The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer 22: 181-187, 2014
6. Li SG, Chen HY, Ou-Yang CS, Wang XX, Yang ZJ, Tong Y and Cho WC: The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-Analysis. PLoS One 8: 28, 2013
7. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J and Lin HS: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24: 303-309, 2004
8. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P and Bergo MO: Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 6: 221ra15, 2014
9. Chandel NS and Tuveson DA: The promise and perils of antioxidants for cancer patients. N Engl J Med 371: 177-178, 2014
10. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA and Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 123: 1227-1239, 2008
11. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA and Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 33: 407-418, 2007
12. Hardeland R, Madrid JA, Tan DX and Reiter RJ: Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 52: 139-166, 2012
13. Sanchez-Hidalgo M, Lee M, de la Lastra CA, Guerrero JM and Packham G: Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. J Pineal Res 53: 366-373, 2012
14. Zhou Q, Gui S and Wang Y: Melatonin Inhibits the migration of human lung adenocarcinoma A549 cell lines involving JNK/MAPK pathway. PLoS One 9: e101132, 2014
15. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res 48: 178-184, 2010
16. Sanchez-Sanchez AM, Martin V, Garcia-Santos G, Rodriguez-Blanco J, Casado-Zapico S, Suarez-Garnacho S, Antolin I and Rodriguez C: Intracellular redox state as determinant for melatonin antiproliferative vs. cytotoxic effects in cancer cells. Free Radic Res 45: 1333-1341, 2011
17. Plaimee P, Khamphio M, Weerapreeyakul N, Barusrux S and Johns NP: Immunomodulatory effect of melatonin in SK-LU-1 human lung adenocarcinoma cells co-cultured with peripheral blood mononuclear cells. Cell Prolif 47: 406-415, 2014
18. Laothong U, Pinlaor P, Boonsiri P, Pairojkul C, Priprem A, Johns NP, Charoensuk L, Intuyod K and Pinlaor S: Melatonin inhibits cholangiocarcinoma and reduces liver injury in Opisthorchis viverrini-infected and N-nitrosodimethylamine-treated hamsters. J Pineal Res 55: 257-266, 2013
19. Bilginoglu A, Aydin D, Ozsoy S and Aygun H: Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Turk Kardiyol Dern Ars 42: 265-273, 2014
20. Lee IC, Kim SH, Lee SM, Baek HS, Moon C, Park SC, Kim HC and Kim JC: Melatonin attenuates gentamicin-induced nephrotoxicity and oxidative stress in rats. Arch Toxicol 86: 1527-1536, 2012
21. Ilbey YO, Ozbek E, Simsek A, Otunctemur A, Cekmen M and Somay A: Potential chemoprotective effect of melatonin in cyclophosphamide-And cisplatin-induced testicular damage in rats. Fertil Steril 92: 1124-1132, 2009
22. Mills E, Wu P, Seely D and Guyatt G: Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-Analysis. J Pineal Res 39: 360-366, 2005
23. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ and Mills E: Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-Analysis of randomized trials. Integr Cancer Ther 21: 21, 2011
24. Wang Y-M, Jin B-Z, Ai F, Duan C-H, Lu Y-Z, Dong T-F and Fu Q-l: The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-Analysis of randomized controlled trials. Cancer Chemother Pharmacol 69: 1213-1220, 2012
25. Levin RD, Daehler MA, Grutsch JF, Quiton J, Lis CG, Peterson C, Gupta D, Watson K, Layer D, Huff-Adams S, Desai B, Sharma P, Wallam M, Delioukina M, Ball P, Bryant M, Ashford M, Copeland D, Ohmori M, Wood PA and Hrushesky WJ: Circadian function in patients with advanced non-small cell lung cancer. Br J Cancer 93: 1202-1208, 2005
26. Johns J, Prachacktam S and Chenboonthai C: Development of A dosage form of the pineal hormone melatonin for use with adjuvant chemotherapy. In: 5th Indochina Conference on Pharmaceutical Sciences. Bangkok, Thailand, 21-24 November 2007
27. Pratheepawanit N, Lerkiatbundit S, Thienthong S, Krisanaprakornkit W, Limwattananon C and Pakkhem A: Validation of FACT-G (Thai version) in low literate patients. Patient Reported Outcomes Newsletter 34: 9-10, 2005
28. Lissoni P, Chilelli M, Villa S, Cerizza L and Tancini G: Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35: 12-15, 2003
29. Chanvorachote P, Luanpitpong S, Chunhacha P, Promden W and Sriuranpong V: Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient. Oncol Lett 4: 252-256, 2012
30. Lissoni P: Is there a role for melatonin in supportive care? Support Care Cancer 10: 110-116, 2002
31. Havelka AM, Berndtsson M, Olofsson MH, Shoshan MC and Linder S: Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an offtarget effect? Mini Rev Med Chem 7: 1035-1039, 2007
32. Goncalves MS, Silveira AF, Teixeira AR and Hyppolito MA: Mechanisms of cisplatin ototoxicity: theoretical review. J Laryngol Otol 127: 536-541, 2013
33. Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ and Osanto S: Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 9: 1331-1337, 1998
34. Zhang J, Zhang LL, Shen L, Xu XM and Yu HG: Regulation of AKT gene expression by cisplatin. Oncol Lett 5: 756-760, 2013
35. Drayton RM and Catto JW: Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther 12: 271-281, 2012
36. Bennukul K, Numkliang S and Leardkamolkarn V: Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions. World J Hepatol 6: 230-242, 2014
37. Johns NP and Johns JR: Assessment of 8-isoprostane (8-isoPGF2alpha) in urine of non-small cell lung cancer (NSCLC) patients undergoing chemotherapy. Asian Pac J Cancer Prev 13: 775-780, 2012
38. Loft S, Svoboda P, Kawai K, Kasai H, Sorensen M, Tjonneland A, Vogel U, Moller P, Overvad K and Raaschou-Nielsen O: Association between 8-oxo-7, 8-dihydroguanine excretion and risk of lung cancer in a prospective study. Free Radic Biol Med 52: 167-172, 2012
39. Jaruga P and Dizdaroglu M: Repair of products of oxidative DNA base damage in human cells. Nucleic Acids Res 24: 1389-1394, 1996.